Curriculum Vitae

EILEEN M. PALACE, Ph.D.

Curriculum Vitae
July 2021

President and Director
The Center for Sexual Health, APC
Telephone: (504) 615-3434 (c)
1999-Present

Clinical Associate Professor
Department of Obstetrics and Gynecology
Tulane University School of Medicine
1415 Tulane Avenue
New Orleans, LA 70112
1999-Present

Clinical Psychologist – Relationship Series
WWL-TV Channel 4 Morning News:
Live with Eric Paulson & Sheba Turk
April 2009-Present

EDUCATION

1991 Ph.D., Clinical Psychology (APA Approved)
University of British Columbia, Vancouver, BC

1991-92 Clinical Internship (APA approved)
Department of Psychiatry and Neurology
Tulane University Medical Center, School of Medicine
New Orleans, LA

1988 M.A. Psychology
University of British Columbia, Vancouver, BC

1985-86 M.S. Experimental Psychology (1 year)
Eastern Washington University, Cheney, WA

1984-85 Postbaccalaureate, Psychology
University of Washington, Seattle, WA

1981 B.A. with Honors, Psychology
Whitman College, Walla Walla, WA

FACULTY APPOINTMENTS

1999- Clinical Associate Professor
Department of Obstetrics and Gynecology
Tulane University School of Medicine, New Orleans, LA

1996-99 Associate Professor
Department of Psychiatry and Neurology
Department of Obstetrics and Gynecology
Department of Urology
Department of Surgery
Tulane University School of Medicine, New Orleans, LA

1992-96 Assistant Professor
Department of Psychology
University of Minnesota, Minneapolis, MN

1992-96 Adjunct Assistant Professor
Department of Family Practice and Community Health
University of Minnesota, Medical School, Minneapolis, MN

PREVIOUS POSITIONS/PROFESSIONAL EXPERIENCE

1996-99 Director
The Center for Sexual Health
Tulane University Hospital & Clinic, New Orleans, LA

1992-96 Clinical Psychologist, private practice
Department of Psychology
University of Minnesota, Minneapolis, MN

1991-92 Predoctoral Intern:
Adult Psychiatry Inpatient Unit
Department of Psychiatry and Neurology
Tulane University Medical Center, School of Medicine, New Orleans, LA

Sexual Dysfunction, Impotence, and Infertility Clinics
Department of Urology
Tulane University Medical Center, School of Medicine, New Orleans, LA

Obsessive-Compulsive Disorders Clinic
Department of Psychiatry and Neurology
Tulane University Medical Center, School of Medicine, New Orleans, LA

1986-91 Director, Sexual Psychophysiology Project and Laboratory
University of British Columbia Psychology Clinic
Department of Psychology
University of British Columbia, Vancouver, BC

1988 Reproductive and Sexual Medicine Clinic
Departments of Urology and Psychiatry & Behavioral Sciences
University of Washington, School of Medicine, Seattle, WA1986-88
University of British
Columbia Psychology Clinic
Department of Psychology
University of British Columbia, Vancouver, BC

1986-87 Research Assistantship, Biopsychology
Department of Psychology
University of British Columbia, Vancouver, BC

1985-86 Research Assistantship, Psychophysiology
Department of Psychology
Eastern Washington University, Cheney, WA

1984-85 Research Assistant, Clinical Psychology
Department of Psychology
University of Washington, Seattle, WA

1983-84 Research Assistant, Obstetrics and Gynecology
Laboratory Technician, Counselor
The Women’s Health Care Clinic, Seattle, WA
OB/GYN private practice, Seattle, WA

LICENSURE

Licensed Clinical Psychologist, State of Louisiana: License #814

ACADEMIC HONORS & AWARDS

• University of Minnesota Graduate School Faculty Summer Research Fellowship, 1995
• University of Minnesota Graduate School Faculty Summer Research Fellowship, 1993
• University of British Columbia Graduate Fellowship, 1990-91
• Izaak Walton Killam Predoctoral Fellowship, 1989-90
• Izaak Walton Killam Predoctoral Fellowship, 1988-89
• University of British Columbia Graduate Summer Fellowship, 1988
• Whitman College List of Academic Distinction, 1977-81

PROFESSIONAL SOCIETIES

American Psychological Association
Division 12, Clinical Psychology
Division 35, Psychology of Women
Division 38, Health Psychology
International Academy of Sex Research
Society for the Scientific Study of Sexuality

PROFESSIONAL ACTIVITIES

International Committees:
Scientific Program Committee, International Academy of Sex Research (1996-1997)

Editorial Board member for (past):
Journal of Psychology and Human Sexuality

Consulting Editor for (past):
Psychophysiology

Journals Reviewed for:
Journal of Abnormal Psychology
Journal of Behavior Therapy and Experimental Psychiatry
Journal of Consulting and Clinical Psychology
Psychological Assessment

Publishers Reviewed for:
Harper Collins College Publishers
Oxford University Press

GRANTS

University of British Columbia Humanities & Social Sciences Research Grant (1987-88).
Principal Investigator. Title: The Effect of Anxiety on Arousal in Sexual Dysfunction,
(Total Award = $4,898).

University of British Columbia Humanities & Social Sciences Research Grant (1988-89).
Principal Investigator. Title: Investigating the Validity of an Improved Radiotelemetric
Instrument for Measuring Female Sexual Arousal, (Total Award = $1,900).

University of British Columbia Humanities & Social Sciences Research Grant (1989-90).
Principal Investigator. Title: The Modification of Cognitive Expectancy by False VBV Feedback
in the Treatment of Sexually Dysfunctional Women, (Total Award = $ 1,600).

University of British Columbia Humanities & Social Sciences Research Grant (1990-91).
Principal Investigator. Title: The Modification of Dysfunctional Patterns of Sexual Arousal
through False Physiological Feedback and Sympathetic Activation, (Total Award = $4,987).

National Institute of Mental Health, Clinical Research Training Grant (1993-97).
Clinical Training Faculty. Title: Neurobehavioral Aspects of Personality and Psychopathology,
(Total Award =$339,721).

University of Minnesota Graduate School Grant-in-Aid of Research, Artistry and Scholarship
(1992-94).
Principal Investigator. Title: Autonomic Arousal and Biofeedback-Facilitated Sexual Response in
Dysfunctional Women, (Total Award = $16,139).
University of Minnesota Graduate School Grant-in-Aid of Research, Artistry and Scholarship
(1993-96).
Principal Investigator. Title: Role of Sympathetic Activation in Sexual Response,
(Total Award = $22,900).

Pfizer Global Research & Development.
Principal Investigator and Female Sexual Dysfunction Expert. Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose, Multi-Center Study to Evaluate the Efficacy, Safety and Toleration of Oral Viagra® Administered for 12 Weeks to Women who are either Post-Menopausal or Post-Hysterectomy, who have Physiologic Levels of Estrogen and Testosterone and who have been Diagnosed with Female Sexual Arousal Disorder.

Pfizer Global Research & Development.
Principal Investigator. Title: A Double-Blind Placebo-Controlled, Parallel Group Design Dose-Ranging Study of Three Doses of Lasofoxifene vs. Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women.

Pfizer Global Research & Development.
Principal Investigator, Expert Panel, Sexual History Interview (SHI) Review Panel, and Female Sexual Dysfunction Expert. Title: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multi-Center Study to Evaluate the Efficacy, Safety, and Toleration of Oral Sildenafil Administered for 12 Weeks to Post-Menopausal Women Who Have Been Diagnosed with Female Sexual Arousal Disorder.

Pfizer Global Research & Development.
Principal Investigator, Expert Panel, Sexual History Interview (SHI) Review Panel, and Female Sexual Dysfunction Expert. Title: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multi-Center Study to Evaluate the Efficacy, Safety, and Toleration of Oral Sildenafil Administered for 12 Weeks to Premenopausal Women Who Have Been Diagnosed with Female Sexual Arousal Disorder.

Pfizer Global Research & Development.
Principal Investigator. Title: An Open-Label, Multi-Center Extension Study to Evaluate the Safety, Toleration, and Sustained Efficacy of Oral Sildenafil Administered to Women who have been Diagnosed with Female Sexual Arousal Disorder.

Pfizer Global Research & Development.
Principal Investigator and Female Sexual Dysfunction Expert. Protocol A1481127. Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose, Multi-Center Study to Evaluate the Efficacy, Safety, and Toleration of Oral Sildenafil Administered for 12 Weeks to Pre-Menopausal and Post-Menopausal Women Receiving Hormone Replacement Therapy who have been Diagnosed with Female Sexual Arousal Disorder.

Pfizer Global Research & Development.
Principal Investigator. Title: A Phase III, Open-Label, Multi-Centre Extension Study to Evaluate the Safety, Toleration, and Sustained Efficacy of Oral Sildenafil Administered to Pre-Menopausal and Post-Menopausal Women Receiving Hormone Replacement Therapy who have been Diagnosed with Female Sexual Arousal Disorder.

Pfizer Global Research & Development.
Sub-Investigator. Title: A Phase III Study of the Efficacy and Safety of Lasofoxifene in the Treatment
of Vaginal Atrophy in Postmenopausal Women.

Pfizer Global Research & Development.
Principal Investigator. Title: A Phase 2B. Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390, 957 in Men with Premature Ejaculation.

Pfizer Global Research & Development.
Principal Investigator. Title: A Phase 2 Multi-Center, Open Label Long-Term Extension Trial to Assess the Safety and Sustained Efficacy of Oral UK-390, 957 Administered as Required in Adult Men with Premature Ejaculation.

Pfizer Global Research & Development.
Principal Investigator. Title: A Phase 2B, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Titration Study to Assess the Efficacy and Safety of Oral UK-390, 957 in Men with Premature Ejaculation.

Pfizer Global Research & Development.
Principal Investigator. Title: A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Assess the Time to Onset, Safety, and Toleration of Differing Doses and Combinations of Immediate Release and Modified Release Formulations of UK369, 003 in Adult Male Subjects with Erectile Dysfunction.

Eli Lilly and Company.
Principal Investigator. Title: Raloxifene Alendronate Comparison in Postmenopausal Women with Low Bone Mass.

Organon.
Principal Investigator. Title: A Multicenter, Randomized, Double-Blind, Double Dummy, Group Comparative Trial to Compare the Effects of Tibolone and Transdermal Continuous Combined Estradiol/Norethisterone on the Vaginal Bleeding Pattern, Sexual Desire and Arousal in
Postmenopausal Women with Sexual Dysfunction.

Pfizer Global Research & Development.
Principal Investigator. Title: A Multicenter, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women with Overactive Bladder.

Eli Lilly and Company.
Principal Investigator. Title: Effect of Duloxetine on VLPP and Quantitative Rhabdosphincter EMG Measures in Women with Stress Urinary Incontinence.

Eli Lilly and Company.
Principal Investigator. Title: A Randomized, Double-Blind, Parallel-Design, Placebo Controlled Study to Evaluate the Effects of 5mg Tadalafil and 50 mg Sildenafil Administered Once Daily for 6 Months on Visual Function in Healthy Subjects or Subjects with Mild Erectile Dysfunction.

Eli Lilly and Company.
Principal Investigator. Title: The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 diabetes and Inadequate Glycemic Control.

Palatin Technologies.
Principal Investigator. Title: A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, At-Home Exploratory Study to Evaluate the Efficacy and Safety of Intranasally Administered PT-141 in Subjects with Female Sexual Arousal Disorder (FSAD).

Wyeth Pharmaceuticals.
Principal Investigator. Title: The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS-SR in Women with Vasomotor Symptoms associated with Menopause.

Pfizer Global Research & Development.
Principal Investigator. Title: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of CP-945, 598 in the Treatment of Overweight, Oral Agent-Treated Subjects with Type 2 Diabetes Mellitus.

Pfizer Global Research & Development.
Principal Investigator. Title: A 12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison with Tolterodine ER in Patients with Overactive Bladder.

Novo Nordisk Inc.
Principal Investigator. NN1250-1860: Title: The Effect of Liraglutide compared to Sitagliptin, both in combination with Metformin in Subjects with Type 2 Diabetes. A 26-week, Randomized, Open-Label, Active Comparator, Three-Armed, Parallel-Group, Multi-centre, Multi-National Trial with a 52-Week Extension.

Novo Nordisk Inc.
Principal Investigator. NN1250-3579: Title: A 52-week Randomised, Controlled, Open-Label, Multicentre, Multinational Treat-to-Target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, both Injected Once Daily in Combination with Oral Anti-Diabetic Drugs (OAD), in Subjects with Type 2 Diabetes Mellitus Currently Treated with OAD(s) and Qualifying for more Intensified Treatment.

Novo Nordisk Inc.
Principal Investigator. NN1250-3582: Title: A 52-week Randomised, Controlled, Open-Label, Multicentre, Multinational Treat-to-Target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine both Administered Once Daily in a Basal-Bolus Regimen with Insulin Aspart as Mealtime Insulin ± Treatment with Metformin, ± Pioglitazone in Subjects with Type 2 Diabetes Currently Treated with Insulin Qualifying for Intensified Treatment.

Novo Nordisk Inc.
Principal Investigator. NN1250-3580: Title: A Trial Comparing Efficacy and Safety of NN1250 with Sitagliptin in Insulin Naïve Subjects with Type 2 Diabetes. A 26-Week Randomised, Controlled, Open-Label, Multicentre, Multinational Trial Comparing Efficacy and Safety of SIBA with Sitagliptin as Add-on to Current Oral Antidiabetic Treatment in Insulin-Naïve Subjects with Type 2 Diabetes Mellitus Inadequately Controlled with 1-2 Oral Antidiabetic Drugs (Metformin, Sulphonylurea, Glinides or Pioglitazone).

Novo Nordisk Inc.
Principal Investigator. NN1250-3718: Title: A Trial Comparing the Efficacy and Safety of NN1250 and Insulin Glargine in Subjects with Type 2 Diabetes. A 26-week Randomized, Confirmatory, Controlled, Open-Label, Multicentre, Multinational Treat-to-Target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin Naïve Subjects with Type 2 Diabetes Mellitus Currently Treated with OADs Qualifying for Intensified Treatment.

Novo Nordisk Inc.
Principal Investigator. NN1250-3839: Title: A 16-week, Uncontrolled, Single-Armed, Multicentre, Treat-to-Target Trial Assessing the Implications of Switching from Insulin Glargine Once Daily (OD) to Insulin Degludec 200 U/ml Three Times Weekly in Subjects with Type 2 Diabetes Mellitus Currently Treated with Insulin Glargine OD and Oral Antidiabetic Drugs (OADs).

Novo Nordisk Inc.
Principal Investigator. NN1250-3643: Title: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) with Insulin Glargine Plus OAD(s) in Type 2 Diabetes; A 52-Week Controlled, Open-Label, Multicentre, Multinational, Two-Arm, Parallel Treat-to-Target Extension Trial Comparing the Safety and Efficacy of SIBA and Insulin Glargine, Both Injected Once Daily in Combination with Oral Antidiabetic Drugs (OAD), in Subjects with Type 2 Diabetes Mellitus after a Preceding 52-Week Treatment Period with SIBA or Insulin Glargine Combined with OAD(s) in Trial NN1250-3579.

Novo Nordisk Inc.
Principal Investigator. NN1250-3667: Title: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both with Insulin Aspart as Meal-Time Insulin Plus/Minus OADs in Type 2 Diabetes.

Novo Nordisk Inc.
Principal Investigator. ANA-3786: Title: A Randomized, Controlled, Open-Label, Multicentre, Multinational, Treat-to-Target Trial Investigating the Efficacy and Safety of Intensification with Addition of Bolus Insulin Aspart in Subjects with Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-Diabetic Drugs: Step-Wise Addition Versus Complete Basal-Bolus Therapy.

Novo Nordisk Inc.
Principal Investigator. NN1250-3923: Title: A Trial Comparing the Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Subjects with Type 2 Diabetes Mellitus.

Novo Nordisk Inc.
Principal Investigator. NN1250-3948: Title: A Trial Comparing the Efficacy and Safety of Adding Liraglutide Versus Addition of Insulin Aspart with the Largest Meal to Insulin Degludec, both in Combination with Metformin, in Subjects with Type 2 Diabetes Qualifying for Treatment Intensification.

Novo Nordisk Inc.
Principal Investigator. NN9068-3912: Title: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects with Type 2 Diabetes.

Novo Nordisk Inc.
Principal Investigator. NN1250-3943: Title: A Trial Comparing the Efficacy, Patient-Reported Outcomes and Safety of Insulin Degludec 200 U/mL vs. Insulin Glargine in Subjects with Type 2 Diabetes Mellitus Requiring High-Dose Insulin.

Novo Nordisk Inc.
Principal Investigator. NN2211-3917: Title: The Effect of Liraglutide Versus Placebo when Added to
Basal Insulin Analogues With or Without Metformin in Subjects with Type 2 Diabetes.

Novo Nordisk Inc.
Principal Investigator. NN1250-3944: Title: The Effect of Insulin Degludec in Combination with Liraglutide and Metformin in Subjects with Type 2 Diabetes Qualifying for Treatment Intensification.

Pfizer Global Research & Development.
Principal Investigator. A3051123: Title: A Phase 4, Randomized, Double-Blind, Active and
Placebo-Controlled, Multicenter Study Evaluating the Neuropsychiatric Safety and Efficacy of 12
Weeks Varenicline Tartrate 1mg bid and Bupropion Hydrochloride 150mg bid for Smoking Cessation
in Subjects With and Without a History of Psychiatric Disorders.

Pfizer Global Research & Development.
Principal Investigator. A3051148: Title: A Phase 4, Non-Treatment Follow-Up for Cardiac Assessments Following Use of Smoking Cessation Treatments in Subjects With and Without a History of Psychiatric Disorders.

Novo Nordisk Inc.
Principal Investigator. NN9535-3625: Title: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add-On to Metformin With or Without Sulphonylurea in Insulin-Naïve Subjects with Type 2 Diabetes.

Novo Nordisk Inc.
Principal Investigator. NN9535-3627: Title: Efficacy and Safety of Semaglutide Once-Weekly Versus Placebo as Add-On to Basal Insulin Alone or Basal Insulin in Combination with Metformin in Subjects
with Type 2 Diabetes.

Novo Nordisk Inc.
Principal Investigator. NN9068-4185: Title: A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in subjects with type 2 diabetes mellitus.

Palatin Technologies, Inc.
Principal Investigator. BMT-302 Reconnect Study: Title: A Phase 3, Multicenter, Randomized,
Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcut

This website uses cookies.